```
/* load data */
DATA data:
        INFILE "/home/u63563888/435/homework10/bmt.dat";
        INPUT patient time status rage dage type preg index gvhd;
        IF type = 2 THEN is_type_two = 1; ELSE is_type_two = 0;
        IF type = 3 THEN is type three = 1; ELSE is type three = 0;
        IF _{N} = 1 THEN delete;
RUN:
ods graphics on;
ods pdf file="/home/u63563888/435/homework10/hw10_model_output.pdf";
/* parametric model */
PROC LIFEREG DATA = data;
        CLASS type preg gvhd;
        MODEL time*status(0) = rage dage is_type_two is_type_three
                                                          preg index
gvhd /
                                                         COVB DIST =
weibull;
RUN;
ods pdf close;
ods graphics off;
/* get acceleration factors */
DATA temp;
        LENGTH estimate $ 15;
        INPUT estimate value;
        DATALINES;
                type_three 2.9802
                gvhd_0 2.9207
        ;
RUN:
DATA accel;
        SET temp;
        rel accel = exp(-value);
        reduction = 1/rel accel;
RUN;
ods pdf file="/home/u63563888/435/homework10/aft_vals.pdf";
PROC PRINT DATA = accel; RUN;
ods pdf close;
```

/\*
By running a Weibull AFT model, we saw that the p-values for
model covariates were only significant for two variables:
type 3 leukemia (CML) and gvhd (graft-versus-host disease status).

We can use the formula exp(-alpha) to get relative acceleration factors. The alpha value for type 3 is 2.9802 and the alpha value for not having gvhd compared to having it is 2.9207. Using the previous formula, we get corresponding relative acceleration factors of 0.051 and 0.054 respectively.

This means that if all other variables are controlled, having type 3 leukemia instead of type 1 leukemia (AML) decreases chances of death by a factor of 19.7 and not having graft-versus-host disease rather than having gvhd decreases chances of death by a factor of 18.6.
\*/